FDA Clears Liquid Extended-Release Amphetamine for ADHD
The US Food and Drug Administration (FDA) has approved amphetamine extended-release oral suspension (Adzenys ER, Neos Therapeutics Inc) for attention-deficit/hyperactivity disorder (ADHD) in children aged 6 years and older, the company has announced. The FDA has already approved Neos Therapeutics' amphetamine extended-release orally disintegrating tablets (Adzenys XR-ODT) and the company's methylphenidate extended-release orally disintegrating tablets (Cotempla XR-ODT) for ADHD in children aged 6 years and older.
Other Articles in this Edition
ADHD Kids Can Be Still – If They’re Not Straining Their Brains
The Role Developmental Motor Skills Play in Your Child’s ADHD
FDA Clears Liquid Extended-Release Amphetamine for ADHD
Adult ADHD Patients Want Longer Acting Medications
Shire Presents Data on Efficacy of Mydayis, Unmet Need for Adults With ADHD
Top ADHD Myths and How Adults Can Overcome Them
Why people with ADHD can be successful in business
Duke receives $12.5 million grant to study children with both ADHD and autism
Things Parents Of Children With ADHD Wish Someone Had Told Them